Camzyos: which tox species, and why?

“A consistent finding in all repeat-dose toxicity studies (up to 26 weeks in rats and up to 39 weeks in dogs) was dose-dependent reduction in cardiac contractility.”

“Mavacamten is slightly more potent in the species used for general toxicological assessment, and comparable potencies were exhibited by the recombinant wild type human beta cardiac myosin and five HCM mutants.”

“A consistent finding in all repeat-dose toxicity studies (up to 26 weeks in rats and up to 39 weeks in dogs) was dose-dependent reduction in cardiac contractility.”

“A consistent finding in all repeat-dose toxicity studies (up to 26 weeks in rats and up to 39 weeks in dogs) was dose-dependent reduction in cardiac contractility.”

“Mavacamten was shown to be teratogenic in both rats and rabbits in embryo-fetal developmental studies.”

“Carcinogenicity of mavacamten was studied in the 104-week study with Sprague-Dawley rats and 6 months study with transgenic RasH2 mice.”